Previous 10 | Next 10 |
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. ...
2023-06-26 10:26:50 ET Zymeworks ( NASDAQ: ZYME ) has joined both the Russell 3000, Russell 2000, and the Russell Microcap Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective today after the U.S. market opens. ZYME is -1.3% to $8.0 So...
VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000 ® , and the Russell Mic...
2023-06-22 10:02:12 ET Gainers: TRxADE HEALTH ( MEDS ) +39% . Talaris Therapeutics ( TALS ) +25% . IGM Biosciences ( IGMS ) +11% . Predictive Oncology ( POAI ) +4% . Zymeworks ( ZYME ) +3% . Losers: Innovative Eyewear...
2023-06-20 06:39:41 ET Summary Today, we revisit an oncology focused developmental concern called Zymeworks, Inc. The company continues to advance its lead drug candidate, has a huge potential partnership with Jazz Pharmaceuticals and a large cash hoard. The stock has spent mo...
2023-06-11 13:32:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re willing to attempt a difficult balancing act in seeking out a discount and potentially imminent upside momentum at roughly the same time, these adventurous undervalued growth...
2023-06-05 06:00:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Growth stocks are often expensive in that they trade with high valuations like price-to-earnings (P/E) and price-to-sales (P/S) ratios. Yet, these high valuations might be justified if the ...
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meanin...
2023-05-18 08:47:04 ET Biotechnology company Zymeworks ( NASDAQ: ZYME ) said on Thursday that Neil Klompas will step down from the post of president and COO, effective June 30. Klompas, who was named COO and president in 2022, will remain as a company advisor to ensu...
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas, President and Chief Operating Officer. Mr. Klompas joined Zym...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...